Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanoma.
Sznol
M
M
National Cancer Institute, IL-2/LAK Extramural Working Group, Bethesda, Maryland 20892.
Dutcher
J P
JP
Atkins
M B
MB
Rayner
A R
AR
Margolin
K A
KA
Gaynor
E R
ER
Weiss
G R
GR
Aronson
F
F
Parkinson
D R
DR
Hawkins
M J
MJ
D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000276:immunology*; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary / Q000628:therapy*
D000970:Antineoplastic Agents; D007376:Interleukin-2